Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate
Pulmonary Pharmacology & Therapeutics · 2022-12 · 77 · 102171
DOI: 10.1016/j.pupt.2022.102171 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2022-12. Verfasst von Peter T Daley-Yates und 3 weiteren Autor:innen. Beteiligte Einrichtung: GSK, 980 Great West Rd, Brentford, Middlesex, TW8 9GS, UK. Hauptthemen laut MEDLINE: Hypothalamo-Hypophyseal System, Receptors, Glucocorticoid. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
AIMS: To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF). METHODS: Study 1: Fourteen healthy participants received inhaled and intravenous MF (inhaled dose via Twisthaler) and FP (inhaled dose via Diskus), both given at 400 μg, using a randomised, single-dose, four-way crossover design. Study 2: Twenty-seven participants with mild to moderate asthma, who discontinued their corticosteroid medication for 5 days to obtain a baseline 24 h serum cortisol, received inhaled MF Twisthaler and FP Diskus, both given at 400 μg twice daily (BID), using a randomised, 14-day repeat dose, two-way crossover design. Study 3: Forty-four healthy participants were randomised to a double-blind, placebo-controlled, five-period crossover study where the following treatments were administered via the inhaled route for 7 days: FP Diskus (250, 500, 1000 μg BID), FF Diskus (100, 200, 400, 800, 1600 μg once daily [QD]) or placebo Diskus. In each study, 24-h serial blood samples were collected and assayed to assess concentrations of MF, 6β-hydroxy mometasone, mometasone, FP, FF and cortisol. Pharmacokinetic and serum cortisol parameters were estimated as geometric means and 95% confidence intervals (CI). RESULTS: Study 1: For intravenous MF and FP, respectively: absolute bioavailability was 11.4% (95% CI: 7.5, 17.6) and 7.8% (6.3, 9.6); plasma clearance was 47 L/h (41, 52) and 60 L/h (52, 69); half-life was 7.4 h (6.9, 8.0) and 7.2 h (6.5, 8.0); and volume of distribution was 499 L (439, 567) and 623 L (557, 698). Inhalation of single dose MF or FP did not significantly affect serum cortisol (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, 980 Great West Rd, Brentford, Middlesex, TW8 9GS, UK.
- GSK, Gunnels Wood Rd, Stevenage, Hertfordshire, SG1 2NY, UK. Electronic address: amanda.t.deans@gsk.com.
- GSK, 5 Moore Drive, Research Triangle Park, NC, 27709, USA. Electronic address: rashmi.s.mehta@gsk.com.
- GSK, 980 Great West Rd, Brentford, Middlesex, TW8 9GS, UK. Electronic address: ana.x.sousa@gsk.com.
Förderung
- GlaxoSmithKline
Zitieren
APA
Daley-Yates, P. T., Deans, A., Mehta, R., & Sousa, A. R. (2022). Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Pulmonary Pharmacology & Therapeutics, 77, 102171. https://doi.org/10.1016/j.pupt.2022.102171
Vancouver
Daley-Yates PT, Deans A, Mehta R, Sousa AR. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Pulmonary Pharmacology & Therapeutics. 2022;77:102171. doi:10.1016/j.pupt.2022.102171
BibTeX
@article{DaleyYates2022,
author = {Daley-Yates, Peter T and Deans, Amanda and Mehta, Rashmi and Sousa, Ana R},
title = {Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2022},
volume = {77},
pages = {102171},
doi = {10.1016/j.pupt.2022.102171}
}
EUVIMED